The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.
 
Todd Michael Bauer
Research Funding - Pfizer (Inst)
 
Alice Tsang Shaw
Honoraria - Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Novartis; Pfizer; Roche Pharma AG; Roche/Genentech
Research Funding - ARIAD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Ben Solomon
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Merck; Novartis; Pfizer; Roche Pharma AG
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Roche Pharma AG
 
Benjamin Besse
Research Funding - Pfizer
 
Leonard P. James
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Jill S. Clancy
Employment - inVentiv Health
 
Ganesh Mugundu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jean-Francois Martini
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Patents, Royalties, Other Intellectual Property - Pfizer
 
Antonello Abbattista
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Enriqueta Felip
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis